drugset / Trial / NCT07473102

PET Imaging of MMP Activation in AAA: Clinical Component

NCT07473102 ↗

Phase 0 Recruiting 28 enrolled Washington University School of Medicine
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).

Timeline

Start
2025-11-03
Primary completion
2027-03-31
Completion
2027-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cu-64-RYM2 Unknown — —